# EDGAR Filing Document

**Accession Number:** 0001830214
**File Stem:** 0000950170-23-005511
**Filing Date:** 2023-3
**Character Count:** 57525
**Document Hash:** e6c4194e2e4b536872e26c837ec762d9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-005511.hdr.sgml**: 20230301

**ACCESSION NUMBER**: 0000950170-23-005511

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230301

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230301

**DATE AS OF CHANGE**: 20230301

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ginkgo Bioworks Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001830214
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 872652913
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40097
- **FILM NUMBER:** 23693393

**BUSINESS ADDRESS:**
- **STREET 1:** 27 DRYDOCK AVENUE
- **STREET 2:** 8TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** (877) 442-5362

**MAIL ADDRESS:**
- **STREET 1:** 27 DRYDOCK AVENUE
- **STREET 2:** 8TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Soaring Eagle Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Spinning Eagle Acquisition Corp.
- **DATE OF NAME CHANGE:** 20201027

?xml version="1.0" encoding="ASCII"? 8-K

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported):** March 1, 2023

------

GINKGO BIOWORKS HOLDINGS, INC.

**(Exact name of registrant as specified in its charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-40097 | 87-2652913 |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

27 Drydock Avenue

8th Floor

Boston**,** MA 02210

**(Address of principal executive offices, including zip code)**

**Registrant's telephone number, including area code:** (877) 422-5362

**(Former name or former address, if changed since last report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Class A common stock, par value $0.0001 per share | DNA | NYSE |
| Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share | DNA.WS | NYSE |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02. Results of Operations and Financial Condition.**

On March 1, 2023, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the fourth quarter 2022 and year ended December 31, 2022. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 99.1 | [<u>Press Release, issued by Ginkgo Bioworks Holdings, Inc. on March 1, 2023</u>](dna-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **GINKGO BIOWORKS HOLDINGS, INC.** | **GINKGO BIOWORKS HOLDINGS, INC.** |
| Date: March 1, 2023 | By: | /s/ Mark Dmytruk |
|  | Name: | Mark Dmytruk |
|  | Title: | Chief Financial Officer |

---

------

## Ex-99

**Exhibit 99.1**

![img197909486_0.jpg](img197909486_0.jpg)

**Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results**

$478 million of total revenue in 2022, representing an increase of 52% over 2021 and toward the high end of guidance

59 new Cell Programs added in 2022, representing 90% growth over 2021 and toward the high end of guidance

Year end cash balance of over $1.3 billion provides meaningful multi-year runway as we drive towards profitability

**BOSTON -- March 1, 2023 --** Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2022. The update, including a webcast slide presentation with additional details on the fourth quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

"We added 59 new programs to the cell programming platform in 2022 as our team delivered toward the high end of our program guidance," said Jason Kelly, co-founder and CEO of Ginkgo. "This outstanding performance illustrates strong growth in customer demand as our capabilities progress. Each new program is valuable to Ginkgo, expanding and scaling our platform capabilities and driving financial value. Importantly, we continue to see great sales momentum with biopharma customers, who represent both the most sophisticated and largest end market opportunity for us today. Our long-term Biosecurity strategy is also developing nicely as we build a strong base of more recurring biosecurity revenue through our biosurveillance and international partnerships on top of any potential continued COVID-19 testing. I'm very excited about Ginkgo's ability to drive growth and platform improvements in 2023, and our cash balance of over $1.3 billion provides us significant flexibility in an uncertain macroeconomic environment."

**Recent Business Highlights & Strategic Positioning**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Added 20 new Cell Programs to the Foundry platform in the fourth quarter of 2022, for a total of 59 new programs in the full year, representing 90% growth over 2021

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Generated Foundry revenue of $144 million in 2022, representing growth of 27% over 2021

oAs previously announced, a subset of targeted milestones that were expected to contribute to 2022 Foundry revenue remained unearned in the fourth quarter, though Ginkgo continues to work toward the achievement of these milestones

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Concentric by Ginkgo, Ginkgo's biosecurity and public health offering, generated $334 million in Biosecurity revenue in 2022, representing growth of 66% over 2021 and more than doubling the original guidance provided in March 2022

oConcentric continued to expand the Traveler-Based Genomic Surveillance program with Centers for Disease Control and Prevention (CDC) and XpresCheck, adding three new participating airports (for a total of seven) and completing a recent pilot initiative to detect influenza variants in addition to SARS-CoV-2

oConcentric continues to establish international partnerships, including in Australia, Botswana, Qatar, Rwanda, Saudi Arabia, the United Kingdom, and Ukraine, as well as multilateral partnerships with Africa CDC and African Risk Capacity

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Downstream value – which consists of potential value to Ginkgo from its Cell Engineering customers and includes potential royalties, milestone payments, and equity interests – is an important component of the financial potential of most programs, and Ginkgo added over $2.0 billion in aggregate revenue potential from downstream milestone payments in connection with new Cell Programs in 2022. This is in addition to the financial potential from royalties and equity consideration obtained in connection with those Cell Programs

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Ginkgo launched Ginkgo Enzyme Services, which aims to solve challenges for R&D teams developing enzymes, from discovery of novel enzyme activity through optimization of enzyme function and large scale manufacturing

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Ginkgo opened Bioworks7, which adds 6,600 square feet of Biosafety Level 2 (BSL-2) lab space at Ginkgo's headquarters in Boston's Seaport District, expanding its mammalian foundry platform to provide significant runway to support new program additions in the pharma & biotech vertical

**Fourth Quarter 2022 Financial Highlights**

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Fourth quarter 2022 Total revenue of $98 million, down from $148 million in the comparable prior year period, a decrease of 34%, due to the expected reduction in K-12 COVID-19 testing services

oFourth quarter 2022 Foundry revenue of $53 million, up from $34 million in the comparable prior year period, an increase of 56%

oFourth quarter 2022 Biosecurity revenue of $45 million, down from $114 million in the comparable prior year period, a decrease of 61%, with fourth quarter 2022 Biosecurity gross profit margin of 33%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Fourth quarter 2022 Loss from operations of $(235) million (inclusive of stock-based compensation expense of $111 million), compared to Loss from operations of $(1,685) million (inclusive of stock-based compensation expense of $1,673 million) in the comparable prior year period. The stock-based compensation expense primarily relates to the continued GAAP accounting for the modification of restricted stock units issued prior to becoming a public company, as disclosed in our annual report on Form 10-K filed with the SEC on March 29, 2022

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Fourth quarter 2022 Adjusted EBITDA of $(80) million, down from $1 million in the comparable prior year period

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Cash and cash equivalents balance as of the end of the fourth quarter of over $1.3 billion puts Ginkgo in a strong financial position to pursue its strategic objectives

**Full Year 2022 Financial Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Full year 2022 Total revenue of $478 million, up from $314 million in the prior year, an increase of 52%

oFull year 2022 Foundry revenue of $144 million, up from $113 million in the prior year, an increase of 27%

oFull year 2022 Biosecurity revenue of $334 million, up from $201 million in the prior year, an increase of 66%, with full year 2022 Biosecurity gross profit margin of 39%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Full year 2022 Loss from operations of $(2.2) billion (inclusive of stock-based compensation expense of $1.9 billion), compared to $(1.8) billion (inclusive of stock-based compensation expense of $1.7 billion) in the prior year

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Full year 2022 Adjusted EBITDA of $(173) million, down from $(106) million in the prior year

**Full Year 2023 Guidance** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Ginkgo expects to add 100 new Cell Programs to the Foundry platform in 2023

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Ginkgo expects Total revenue of at least $275 million in 2023

oGinkgo expects Foundry revenue of at least $175 million in 2023. This guidance excludes the impact of any downstream value share revenue, although Ginkgo is still working toward the achievement of downstream value share in 2023

oWhile Biosecurity remains an uncertain business, Ginkgo expects Biosecurity revenue in 2023 of at least $100 million, with nearly half of this revenue expected to come from emerging product lines that are more recurring in nature, such as federal and international partnerships supporting pathogen monitoring and biosecurity infrastructure development

**Timing of Filing Annual Report on Form 10-K** 

Ginkgo became a large accelerated filer as of December 31, 2022, which resulted in a filing deadline 30 days ahead of our deadline last year. While we believe our financial statements are final, additional time is necessary to finalize materials required to complete the audit of our annual financial statements, including accompanying footnote disclosures.

As such, we will be filing a Form 12b-25 for an automatic extension to our Form 10-K filing deadline. We are working diligently to file our Annual Report as soon as practicable and within the automatic extension period of fifteen calendar days from the prescribed due date.

**Conference Call Details**

Ginkgo will host a videoconference today, Wednesday, March 1, 2023, beginning at 4:30 p.m. ET. The presentation will include an overview of the fourth quarter and full year financial performance, recent business updates, a discussion on Ginkgo's outlook, as well as a moderated question and answer session.

To ask a question ahead of the presentation, please submit your questions to @Ginkgo on Twitter (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.

------

A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.<br>**Ginkgo Investor Website:** https://investors.ginkgobioworks.com/events/

**<u>Audio-Only Dial Ins:</u>**<br> +1 646 876 9923 (New York)

+1 301 715 8592 (Washington DC)

+1 312 626 6799 (Chicago)

+1 669 900 6833 (San Jose)

+1 253 215 8782 (Tacoma)

+1 346 248 7799 (Houston)

+1 408 638 0968 (San Jose)

**Webinar ID: 999 3790 5942**

If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our web site at https://investors.ginkgobioworks.com/events/ for updated dial-in information.

**About Ginkgo Bioworks**

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as Twitter (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), or LinkedIn.

**Forward-Looking Statements of Ginkgo Bioworks**

This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, current expectations, operations and anticipated results of operations, both business and financial, including the potential for future revenue related to downstream value in the form of potential future milestone payments and royalties and/or equity consideration, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19 testing business, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) our ability to realize the expected benefits of merger and acquisition transactions, (vii) the outcome of any legal proceedings against Ginkgo, including as a result of recent acquisitions, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (x) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's most recent quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC"), and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

**Use of Non-GAAP Financial Measures**

Certain of the financial measures included in this release, including Adjusted EBITDA, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect

------

future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures.

 **Ginkgo Bioworks Contacts:** 

**INVESTOR CONTACT:**

**investors@ginkgobioworks.com** 

**MEDIA CONTACT:**

**press@ginkgobioworks.com** 

------

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. |
| &nbsp;&nbsp;Condensed Consolidated Balance Sheets  | &nbsp;&nbsp;Condensed Consolidated Balance Sheets  | &nbsp;&nbsp;Condensed Consolidated Balance Sheets  |
| &nbsp;&nbsp;(in thousands, except per share data, unaudited) | &nbsp;&nbsp;(in thousands, except per share data, unaudited) | &nbsp;&nbsp;(in thousands, except per share data, unaudited) |
|  | &nbsp;&nbsp;**As of December 31,** | &nbsp;&nbsp;**As of December 31,** |
|  | &nbsp;&nbsp;**2022** | &nbsp;&nbsp;**2021** |
| &nbsp;&nbsp;**Assets** |  |  |
| &nbsp;&nbsp;Current assets: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | &nbsp;&nbsp; $1315792  | &nbsp;&nbsp; $1550004  |
| &nbsp;&nbsp;Accounts receivable, net | &nbsp;&nbsp;80907  | &nbsp;&nbsp;131544  |
| &nbsp;&nbsp;Accounts receivable - related parties | &nbsp;&nbsp;1558  | &nbsp;&nbsp;4598  |
| &nbsp;&nbsp;Inventory, net | &nbsp;&nbsp;4364  | &nbsp;&nbsp;3362  |
| &nbsp;&nbsp;Prepaid expenses and other current assets | &nbsp;&nbsp;47458  | &nbsp;&nbsp;33537  |
| &nbsp;&nbsp;Total current assets | &nbsp;&nbsp;1450079 | &nbsp;&nbsp;1723045 |
| &nbsp;&nbsp;Property and equipment, net | &nbsp;&nbsp;314773  | &nbsp;&nbsp;145770  |
| &nbsp;&nbsp;Operating lease right-of-use assets | &nbsp;&nbsp;400762  | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Investments | &nbsp;&nbsp;112188  | &nbsp;&nbsp;102037  |
| &nbsp;&nbsp;Equity method investments | &nbsp;&nbsp;1543  | &nbsp;&nbsp;13194  |
| &nbsp;&nbsp;Intangible assets, net | &nbsp;&nbsp;111041  | &nbsp;&nbsp;21642  |
| &nbsp;&nbsp;Goodwill | &nbsp;&nbsp;60210  | &nbsp;&nbsp;21312  |
| &nbsp;&nbsp;Other non-current assets | &nbsp;&nbsp;88725  | &nbsp;&nbsp;43990  |
| &nbsp;&nbsp;Total assets | &nbsp;&nbsp; $2539321  | &nbsp;&nbsp; $2070990  |
| &nbsp;&nbsp;**Liabilities and Stockholders' Equity** |  |  |
| &nbsp;&nbsp;Current liabilities: |  |  |
| &nbsp;&nbsp;Accounts payable | &nbsp;&nbsp; $10451  | &nbsp;&nbsp; $8189  |
| &nbsp;&nbsp;Deferred revenue | &nbsp;&nbsp;47817  | &nbsp;&nbsp;33240  |
| &nbsp;&nbsp;Accrued expenses and other current liabilities | &nbsp;&nbsp;114694  | &nbsp;&nbsp;93332  |
| &nbsp;&nbsp;Total current liabilities | &nbsp;&nbsp;172962  | &nbsp;&nbsp;134761  |
| &nbsp;&nbsp;Non-current liabilities: |  |  |
| &nbsp;&nbsp;Deferred rent, net of current portion | &nbsp;&nbsp;—  | &nbsp;&nbsp;18746  |
| &nbsp;&nbsp;Deferred revenue, net of current portion | &nbsp;&nbsp;174767 | &nbsp;&nbsp;155991  |
| &nbsp;&nbsp;Operating lease liabilities, non-current | &nbsp;&nbsp;413256  | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Lease financing obligation | &nbsp;&nbsp;—  | &nbsp;&nbsp;22283  |
| &nbsp;&nbsp;Warrant liabilities | &nbsp;&nbsp;10868  | &nbsp;&nbsp;135838  |
| &nbsp;&nbsp;Other non-current liabilities | &nbsp;&nbsp;31191  | &nbsp;&nbsp;35992  |
| &nbsp;&nbsp;Total liabilities | &nbsp;&nbsp;803044 | &nbsp;&nbsp;503611  |
| &nbsp;&nbsp;Commitments and contingencies |  |  |
| &nbsp;&nbsp;Stockholders' equity: |  |  |
| &nbsp;&nbsp;Preferred stock, $0.0001 par value | &nbsp;&nbsp;—  | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Common stock, $0.0001 par value | &nbsp;&nbsp; 190  | &nbsp;&nbsp; 161  |
| &nbsp;&nbsp;Additional paid-in capital | &nbsp;&nbsp; 6136378  | &nbsp;&nbsp; 3804844  |
| &nbsp;&nbsp;Accumulated deficit | &nbsp;&nbsp; (4397659) | &nbsp;&nbsp; (2297925) |
| &nbsp;&nbsp;Accumulated other comprehensive loss | &nbsp;&nbsp; (2632) | &nbsp;&nbsp; (1715) |
| &nbsp;&nbsp;Total Ginkgo Bioworks Holdings, Inc. stockholders' equity | &nbsp;&nbsp; 1736277  | &nbsp;&nbsp; 1505365  |
| &nbsp;&nbsp;Non-controlling interest | &nbsp;&nbsp;—  | &nbsp;&nbsp; 62014  |
| &nbsp;&nbsp;Total stockholders' equity | &nbsp;&nbsp; 1736277  | &nbsp;&nbsp; 1567379  |
| &nbsp;&nbsp;Total liabilities and stockholders' equity | &nbsp;&nbsp; $2539321  | &nbsp;&nbsp; $2070990  |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. |
| &nbsp;&nbsp;Condensed Consolidated Statements of Operations and Comprehensive Loss  | &nbsp;&nbsp;Condensed Consolidated Statements of Operations and Comprehensive Loss  | &nbsp;&nbsp;Condensed Consolidated Statements of Operations and Comprehensive Loss  | &nbsp;&nbsp;Condensed Consolidated Statements of Operations and Comprehensive Loss  |
| &nbsp;&nbsp;(in thousands, except share and per share data, unaudited)  | &nbsp;&nbsp;(in thousands, except share and per share data, unaudited)  | &nbsp;&nbsp;(in thousands, except share and per share data, unaudited)  | &nbsp;&nbsp;(in thousands, except share and per share data, unaudited)  |
| &nbsp;&nbsp;**Three Months Ended December 31,** | &nbsp;&nbsp;**Three Months Ended December 31,** | &nbsp;&nbsp;**Year Ended December 31,** | &nbsp;&nbsp;**Year Ended December 31,** |
| &nbsp;&nbsp;**2022** | &nbsp;&nbsp;**2021** | &nbsp;&nbsp;**2022** | &nbsp;&nbsp;**2021** |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;Foundry revenue | &nbsp;&nbsp;Foundry revenue | &nbsp;&nbsp; $53257  | &nbsp;&nbsp; $34156  | &nbsp;&nbsp; $143666  | &nbsp;&nbsp; $112989  |
| &nbsp;&nbsp;Biosecurity revenue: | &nbsp;&nbsp;Biosecurity revenue: |  |  |  |  |
| &nbsp;&nbsp;Product | &nbsp;&nbsp;Product | &nbsp;&nbsp;12431  | &nbsp;&nbsp;8418  | &nbsp;&nbsp;35455  | &nbsp;&nbsp;23040  |
| &nbsp;&nbsp;Service | &nbsp;&nbsp;Service | &nbsp;&nbsp;32597  | &nbsp;&nbsp;105920  | &nbsp;&nbsp;298585  | &nbsp;&nbsp;177808  |
| &nbsp;&nbsp;Total revenue | &nbsp;&nbsp;Total revenue | &nbsp;&nbsp;98285  | &nbsp;&nbsp;148494  | &nbsp;&nbsp;477706  | &nbsp;&nbsp;313837  |
| &nbsp;&nbsp;Costs and operating expenses: | &nbsp;&nbsp;Costs and operating expenses: |  |  |  |  |
| &nbsp;&nbsp;Cost of Biosecurity product revenue | &nbsp;&nbsp;Cost of Biosecurity product revenue | &nbsp;&nbsp;7447  | &nbsp;&nbsp;4832  | &nbsp;&nbsp;20646  | &nbsp;&nbsp;20017  |
| &nbsp;&nbsp;Cost of Biosecurity service revenue | &nbsp;&nbsp;Cost of Biosecurity service revenue | &nbsp;&nbsp;22771  | &nbsp;&nbsp;61746  | &nbsp;&nbsp;183570  | &nbsp;&nbsp;109673  |
| &nbsp;&nbsp;Research and development (1) | &nbsp;&nbsp;Research and development (1) | &nbsp;&nbsp;181155  | &nbsp;&nbsp;985025  | &nbsp;&nbsp;1052643 | &nbsp;&nbsp;1149662 |
| &nbsp;&nbsp;General and administrative (1) | &nbsp;&nbsp;General and administrative (1) | &nbsp;&nbsp;121420  | &nbsp;&nbsp;781626  | &nbsp;&nbsp;1429799 | &nbsp;&nbsp;862952  |
| &nbsp;&nbsp;Total operating expenses | &nbsp;&nbsp;Total operating expenses | &nbsp;&nbsp;332793  | &nbsp;&nbsp;1833229 | &nbsp;&nbsp;2686658 | &nbsp;&nbsp;2142304 |
| &nbsp;&nbsp;Loss from operations | &nbsp;&nbsp;Loss from operations | &nbsp;&nbsp;(234508) | &nbsp;&nbsp;(1684735) | &nbsp;&nbsp;(2208952) | &nbsp;&nbsp;(1828467) |
| &nbsp;&nbsp;Other income (expense): | &nbsp;&nbsp;Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;Interest income | &nbsp;&nbsp;Interest income | &nbsp;&nbsp;11412  | &nbsp;&nbsp;496  | &nbsp;&nbsp;20262  | &nbsp;&nbsp;837  |
| &nbsp;&nbsp;Interest expense | &nbsp;&nbsp;Interest expense | &nbsp;&nbsp;1647  | &nbsp;&nbsp;(551) | &nbsp;&nbsp;(106) | &nbsp;&nbsp;(2373) |
| &nbsp;&nbsp;Gain (loss) on equity method investments | &nbsp;&nbsp;Gain (loss) on equity method investments | &nbsp;&nbsp;10003  | &nbsp;&nbsp;(4663) | &nbsp;&nbsp;(43761) | &nbsp;&nbsp;(77284) |
| &nbsp;&nbsp;Loss on investments | &nbsp;&nbsp;Loss on investments | &nbsp;&nbsp;(13354) | &nbsp;&nbsp;(14552) | &nbsp;&nbsp;(53335) | &nbsp;&nbsp;(11543) |
| &nbsp;&nbsp;Change in fair value of warrant liabilities | &nbsp;&nbsp;Change in fair value of warrant liabilities | &nbsp;&nbsp;28871  | &nbsp;&nbsp;77097  | &nbsp;&nbsp;124970  | &nbsp;&nbsp;58615  |
| &nbsp;&nbsp;Gain on settlement of partnership agreement | &nbsp;&nbsp;Gain on settlement of partnership agreement | &nbsp;&nbsp;—  | &nbsp;&nbsp;23826  | &nbsp;&nbsp;—  | &nbsp;&nbsp;23826  |
| &nbsp;&nbsp;Gain on deconsolidation of subsidiaries | &nbsp;&nbsp;Gain on deconsolidation of subsidiaries | &nbsp;&nbsp;—  | &nbsp;&nbsp;—  | &nbsp;&nbsp;31889  | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Other income (expense), net | &nbsp;&nbsp;Other income (expense), net | &nbsp;&nbsp;7005  | &nbsp;&nbsp;(2596) | &nbsp;&nbsp;7634  | &nbsp;&nbsp;(1733) |
| &nbsp;&nbsp;Total other income (expense), net | &nbsp;&nbsp;Total other income (expense), net | &nbsp;&nbsp;45584  | &nbsp;&nbsp;79057  | &nbsp;&nbsp;87553  | &nbsp;&nbsp;(9655) |
| &nbsp;&nbsp;Loss before income taxes | &nbsp;&nbsp;Loss before income taxes | &nbsp;&nbsp;(188924) | &nbsp;&nbsp;(1605678) | &nbsp;&nbsp;(2121399) | &nbsp;&nbsp;(1838122) |
| &nbsp;&nbsp;Income tax benefit | &nbsp;&nbsp;Income tax benefit | &nbsp;&nbsp;(14770) | &nbsp;&nbsp;(683) | &nbsp;&nbsp;(15027) | &nbsp;&nbsp;(1480) |
| &nbsp;&nbsp;Net loss | &nbsp;&nbsp;Net loss | &nbsp;&nbsp;(174154) | &nbsp;&nbsp;(1604995) | &nbsp;&nbsp;(2106372) | &nbsp;&nbsp;(1836642) |
| &nbsp;&nbsp;Net loss attributable to non-controlling interest | &nbsp;&nbsp;Net loss attributable to non-controlling interest | &nbsp;&nbsp;2390  | &nbsp;&nbsp;(4339) | &nbsp;&nbsp;(1443) | &nbsp;&nbsp;(6595) |
| &nbsp;&nbsp;Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders | &nbsp;&nbsp;Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders | &nbsp;&nbsp; $(176544) | &nbsp;&nbsp; $(1600656) | &nbsp;&nbsp; $(2104929) | &nbsp;&nbsp; $(1830047) |
| &nbsp;&nbsp;Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders: | &nbsp;&nbsp;Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders: |  |  |  |  |
| &nbsp;&nbsp;Basic | &nbsp;&nbsp;Basic | &nbsp;&nbsp; $(0.09)  | &nbsp;&nbsp; $(1.05) | &nbsp;&nbsp; $(1.25) | &nbsp;&nbsp; $(1.35) |
| &nbsp;&nbsp;Diluted | &nbsp;&nbsp;Diluted | &nbsp;&nbsp; $(0.10)  | &nbsp;&nbsp; $(1.10) | &nbsp;&nbsp; $(1.25) | &nbsp;&nbsp; $(1.39) |
| &nbsp;&nbsp;Weighted average common shares outstanding: | &nbsp;&nbsp;Weighted average common shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;Basic | &nbsp;&nbsp;Basic | &nbsp;&nbsp;1854951611 | &nbsp;&nbsp;1531138824  | &nbsp;&nbsp;1679061465 | &nbsp;&nbsp;1359848803 |
| &nbsp;&nbsp;Diluted | &nbsp;&nbsp;Diluted | &nbsp;&nbsp;1856609515 | &nbsp;&nbsp;1531551830  | &nbsp;&nbsp;1679838849 | &nbsp;&nbsp;1360373343 |
| &nbsp;&nbsp;Comprehensive loss: | &nbsp;&nbsp;Comprehensive loss: |  |  |  |  |
| &nbsp;&nbsp;Net loss | &nbsp;&nbsp;Net loss | &nbsp;&nbsp; $(174154) | &nbsp;&nbsp;$(1604995) | &nbsp;&nbsp; $(2106372) | &nbsp;&nbsp; $(1836642) |
| &nbsp;&nbsp;Other comprehensive loss: | &nbsp;&nbsp;Other comprehensive loss: |  |  |  |  |
| &nbsp;&nbsp;Foreign currency translation adjustment | &nbsp;&nbsp;Foreign currency translation adjustment | &nbsp;&nbsp;5278  | &nbsp;&nbsp;(838) | &nbsp;&nbsp;(917) | &nbsp;&nbsp;(1715) |
| &nbsp;&nbsp;Total other comprehensive loss | &nbsp;&nbsp;Total other comprehensive loss | &nbsp;&nbsp;5278  | &nbsp;&nbsp;(838) | &nbsp;&nbsp;(917) | &nbsp;&nbsp;(1715) |
| &nbsp;&nbsp;Comprehensive loss | &nbsp;&nbsp;Comprehensive loss | &nbsp;&nbsp; $(168876) | &nbsp;&nbsp; $(1605833) | &nbsp;&nbsp; $(2107289) | &nbsp;&nbsp; $(1838357) |
| &nbsp;&nbsp;(1) | &nbsp;&nbsp;R&D and G&A expenses included a significant charge for stock-based compensation expense as a result of the modification of the vesting terms of RSUs and all related earnout shares. Total stock-based compensation expense inclusive of employer payroll taxes was allocated as follows (in thousands): | &nbsp;&nbsp;R&D and G&A expenses included a significant charge for stock-based compensation expense as a result of the modification of the vesting terms of RSUs and all related earnout shares. Total stock-based compensation expense inclusive of employer payroll taxes was allocated as follows (in thousands): | &nbsp;&nbsp;R&D and G&A expenses included a significant charge for stock-based compensation expense as a result of the modification of the vesting terms of RSUs and all related earnout shares. Total stock-based compensation expense inclusive of employer payroll taxes was allocated as follows (in thousands): | &nbsp;&nbsp;R&D and G&A expenses included a significant charge for stock-based compensation expense as a result of the modification of the vesting terms of RSUs and all related earnout shares. Total stock-based compensation expense inclusive of employer payroll taxes was allocated as follows (in thousands): | &nbsp;&nbsp;R&D and G&A expenses included a significant charge for stock-based compensation expense as a result of the modification of the vesting terms of RSUs and all related earnout shares. Total stock-based compensation expense inclusive of employer payroll taxes was allocated as follows (in thousands): |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Three Months Ended December 31,** | &nbsp;&nbsp;**Three Months Ended December 31,** | &nbsp;&nbsp;**Year Ended December 31,** | &nbsp;&nbsp;**Year Ended December 31,** |
| &nbsp;&nbsp;**(in thousands)** | &nbsp;&nbsp;**2022** | &nbsp;&nbsp;**2021** | &nbsp;&nbsp;**2022** | &nbsp;&nbsp;**2021** |
| &nbsp;&nbsp;Research and development | &nbsp;&nbsp; $68171  | &nbsp;&nbsp; $930300  | &nbsp;&nbsp; $738821  | &nbsp;&nbsp; $930360  |
| &nbsp;&nbsp;General and administrative | &nbsp;&nbsp;43059  | &nbsp;&nbsp;742543  | &nbsp;&nbsp;1202099  | &nbsp;&nbsp;757247  |
| &nbsp;&nbsp;Total | &nbsp;&nbsp; $111230  | &nbsp;&nbsp; $1672843  | &nbsp;&nbsp; $1940920  | &nbsp;&nbsp; $1687607  |

---

------

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. |
| &nbsp;&nbsp;Condensed Consolidated Statements of Cash Flows  | &nbsp;&nbsp;Condensed Consolidated Statements of Cash Flows  | &nbsp;&nbsp;Condensed Consolidated Statements of Cash Flows  |
| &nbsp;&nbsp;(in thousands, unaudited) | &nbsp;&nbsp;(in thousands, unaudited) | &nbsp;&nbsp;(in thousands, unaudited) |
|  | &nbsp;&nbsp;**Year Ended December 31,** | &nbsp;&nbsp;**Year Ended December 31,** |
|  | &nbsp;&nbsp;**2022** | &nbsp;&nbsp;**2021** |
| &nbsp;&nbsp;**Cash flows from operating activities:** |  |  |
| &nbsp;&nbsp;Net loss | &nbsp;&nbsp; $(2106372) | &nbsp;&nbsp; $(1836642) |
| &nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;Depreciation and amortization | &nbsp;&nbsp;42552  | &nbsp;&nbsp; 29076  |
| &nbsp;&nbsp;Stock-based compensation | &nbsp;&nbsp;1930641 | &nbsp;&nbsp;1606020  |
| &nbsp;&nbsp;Non-cash customer consideration | &nbsp;&nbsp;(34263) | &nbsp;&nbsp; (24185) |
| &nbsp;&nbsp;Loss on equity method investments | &nbsp;&nbsp;43761  | &nbsp;&nbsp; 77284  |
| &nbsp;&nbsp;Loss on investments | &nbsp;&nbsp;53335  | &nbsp;&nbsp; 11543  |
| &nbsp;&nbsp;Change in fair value of notes receivable | &nbsp;&nbsp;(3757) | &nbsp;&nbsp; 3508  |
| &nbsp;&nbsp;Change in fair value of warrant liabilities | &nbsp;&nbsp;(124970) | &nbsp;&nbsp;(58615) |
| &nbsp;&nbsp;Gain on deconsolidation of subsidiaries | &nbsp;&nbsp;(31889) | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Deferred income tax benefit | &nbsp;&nbsp;(14609) | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Loss on disposal of equipment | &nbsp;&nbsp;3091  | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Non-cash lease expense | &nbsp;&nbsp;19082  | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Amortization of finance lease right-of-use assets | &nbsp;&nbsp;1871  | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Non-cash severance and retention bonus expense associated with an acquisition | &nbsp;&nbsp;6152  | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Other non-cash activity | &nbsp;&nbsp;183  | &nbsp;&nbsp;(270) |
| &nbsp;&nbsp;**Changes in operating assets and liabilities:** |  |  |
| &nbsp;&nbsp;Accounts receivable | &nbsp;&nbsp;55024  | &nbsp;&nbsp; (114094) |

---

------

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Prepaid expenses and other current assets | &nbsp;&nbsp;(8687) | &nbsp;&nbsp; (2981) |
| &nbsp;&nbsp;Inventory | &nbsp;&nbsp;164  | &nbsp;&nbsp;(626) |
| &nbsp;&nbsp;Operating lease right-of-use assets | &nbsp;&nbsp;13233  | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Other non-current assets | &nbsp;&nbsp;921  | &nbsp;&nbsp;(539) |
| &nbsp;&nbsp;Accounts payable | &nbsp;&nbsp;(10844) | &nbsp;&nbsp; (2247) |
| &nbsp;&nbsp;Accrued expenses and other current liabilities | &nbsp;&nbsp;(39639) | &nbsp;&nbsp; 44796  |
| &nbsp;&nbsp;Deferred revenue, current and non-current | &nbsp;&nbsp;(36417) | &nbsp;&nbsp; (10498) |
| &nbsp;&nbsp;Operating lease liabilities, current and non-current | &nbsp;&nbsp;(10792) | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Deferred rent, non-current | &nbsp;&nbsp;—  | &nbsp;&nbsp; 6032  |
| &nbsp;&nbsp;Other non-current liabilities | &nbsp;&nbsp; 31  | &nbsp;&nbsp; 18620  |
| &nbsp;&nbsp;Net cash used in operating activities | &nbsp;&nbsp; (252198) | &nbsp;&nbsp; (253818) |
| &nbsp;&nbsp;**Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;Purchases of property and equipment | &nbsp;&nbsp;(52271) | &nbsp;&nbsp;(56521) |
| &nbsp;&nbsp;Deconsolidation of subsidiaries - cash | &nbsp;&nbsp;(55721) | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Business acquisitions, net of cash acquired | &nbsp;&nbsp;82367  | &nbsp;&nbsp;(12040) |
| &nbsp;&nbsp;Asset acquisitions, net of cash acquired | &nbsp;&nbsp;(7639) | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Purchases of notes receivable | &nbsp;&nbsp;(40000) | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Proceeds from notes receivable | &nbsp;&nbsp;10000  | &nbsp;&nbsp;304  |
| &nbsp;&nbsp;Purchase of investment in equity securities | &nbsp;&nbsp;(3691) | &nbsp;&nbsp;(5000) |
| &nbsp;&nbsp;Other | &nbsp;&nbsp;(439) | &nbsp;&nbsp;—  |
| &nbsp;&nbsp;Net cash used in investing activities | &nbsp;&nbsp; (67394) | &nbsp;&nbsp; (73257) |
| &nbsp;&nbsp;**Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;Proceeds from reverse recapitalization, net of redemptions of $867,253 and offering costs of $108,118 | &nbsp;&nbsp;—  | &nbsp;&nbsp;1509629  |
| &nbsp;&nbsp;Proceeds from exercise of stock options | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;240  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;167  |
| &nbsp;&nbsp;Repurchases of common stock | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;—  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(24998) |
| &nbsp;&nbsp;Taxes paid related to net share settlement of equity awards | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(981) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9463) |
| &nbsp;&nbsp;Principal payments on finance/capital leases and lease financing obligation | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1237) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1123) |
| &nbsp;&nbsp;Contributions from non-controlling interests | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;—  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59933  |
| &nbsp;&nbsp;Proceeds from public offering, net of issuance costs | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99303  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;—  |
| &nbsp;&nbsp;Proceeds from issuance of Series E convertible preferred stock, net of issuance costs | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;—  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;—  |
| &nbsp;&nbsp;Contingent consideration payment | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(521) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;—  |
| &nbsp;&nbsp;Payment of equity issuance costs | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1467) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;—  |
| &nbsp;&nbsp;Net cash provided by financing activities | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;95337  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1534145  |
| &nbsp;&nbsp;Effect of foreign exchange rates on cash and cash equivalents | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;908  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(19) |
| &nbsp;&nbsp;Net (decrease) increase in cash, cash equivalents and restricted cash | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(223347) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1207051  |
| &nbsp;&nbsp;Cash and cash equivalents, beginning of period | &nbsp;&nbsp;1550004  | &nbsp;&nbsp;380801  |
| &nbsp;&nbsp;Restricted cash, beginning of period | &nbsp;&nbsp;42924  | &nbsp;&nbsp;5076  |
| &nbsp;&nbsp;Cash, cash equivalents and restricted cash, beginning of period | &nbsp;&nbsp;1592928  | &nbsp;&nbsp;385877  |
| &nbsp;&nbsp;Cash and cash equivalents, end of period | &nbsp;&nbsp;1315792 | &nbsp;&nbsp;1550004 |
| &nbsp;&nbsp;Restricted cash, end of period | &nbsp;&nbsp;53789  | &nbsp;&nbsp;42924  |
| &nbsp;&nbsp;Cash, cash equivalents and restricted cash, end of period | &nbsp;&nbsp; $1369581  | &nbsp;&nbsp; $1592928  |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. |
| &nbsp;&nbsp;Selected Non-GAAP Financial Measures | &nbsp;&nbsp;Selected Non-GAAP Financial Measures | &nbsp;&nbsp;Selected Non-GAAP Financial Measures | &nbsp;&nbsp;Selected Non-GAAP Financial Measures | &nbsp;&nbsp;Selected Non-GAAP Financial Measures | &nbsp;&nbsp;Selected Non-GAAP Financial Measures |
| &nbsp;&nbsp;(in thousands, unaudited) | &nbsp;&nbsp;(in thousands, unaudited) | &nbsp;&nbsp;(in thousands, unaudited) | &nbsp;&nbsp;(in thousands, unaudited) | &nbsp;&nbsp;(in thousands, unaudited) | &nbsp;&nbsp;(in thousands, unaudited) |
|  |  | &nbsp;&nbsp;**Three Months Ended December 31,** | &nbsp;&nbsp;**Three Months Ended December 31,** | &nbsp;&nbsp;**Year Ended December 31,** | &nbsp;&nbsp;**Year Ended December 31,** |
|  |  | &nbsp;&nbsp;**2022** | &nbsp;&nbsp;**2021** | &nbsp;&nbsp;**2022** | &nbsp;&nbsp;**2021** |
| &nbsp;&nbsp;Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders | &nbsp;&nbsp;Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders | &nbsp;&nbsp; $(176544) | &nbsp;&nbsp; $(1600656) | &nbsp;&nbsp; $(2104929) | &nbsp;&nbsp; $(1830047) |
| &nbsp;&nbsp;Interest income | &nbsp;&nbsp;Interest income | &nbsp;&nbsp;(11412) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(496) | &nbsp;&nbsp; (20262) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(837) |
| &nbsp;&nbsp;Interest expense | &nbsp;&nbsp;Interest expense | &nbsp;&nbsp;(1647) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;551  | &nbsp;&nbsp;106  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2373  |
| &nbsp;&nbsp;Income tax benefit | &nbsp;&nbsp;Income tax benefit | &nbsp;&nbsp;(14770) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(683) | &nbsp;&nbsp; (15027) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1480) |
| &nbsp;&nbsp;Depreciation and amortization | &nbsp;&nbsp;Depreciation and amortization | &nbsp;&nbsp;13950  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8003  | &nbsp;&nbsp; 42552  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29076  |
| &nbsp;&nbsp;**EBITDA** | &nbsp;&nbsp;**EBITDA** | &nbsp;&nbsp;(190423) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1593281) | &nbsp;&nbsp;(2097560) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1800915) |
| &nbsp;&nbsp;Stock-based compensation (1) | &nbsp;&nbsp;Stock-based compensation (1) | &nbsp;&nbsp;111230  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1672843  | &nbsp;&nbsp;1940920  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1687607  |
| &nbsp;&nbsp;(Gain) loss on equity method investments (2) | &nbsp;&nbsp;(Gain) loss on equity method investments (2) | &nbsp;&nbsp;(7612) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4080  | &nbsp;&nbsp; 45315  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;74445  |
| &nbsp;&nbsp;Loss on investments | &nbsp;&nbsp;Loss on investments | &nbsp;&nbsp;13354  | &nbsp;&nbsp; 14552  | &nbsp;&nbsp; 53335  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11543  |
| &nbsp;&nbsp;Change in fair value of warrant liabilities | &nbsp;&nbsp;Change in fair value of warrant liabilities | &nbsp;&nbsp;(28871) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(77097) | &nbsp;&nbsp; (124970) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(58615) |
| &nbsp;&nbsp;Gain on settlement of partnership agreement | &nbsp;&nbsp;Gain on settlement of partnership agreement | &nbsp;&nbsp; —  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(23826) | &nbsp;&nbsp; —  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(23826) |
| &nbsp;&nbsp;Gain on deconsolidation of subsidiaries | &nbsp;&nbsp;Gain on deconsolidation of subsidiaries | &nbsp;&nbsp; —  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;—  | &nbsp;&nbsp; (31889) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;—  |
| &nbsp;&nbsp;Merger and acquisition related expenses (3) | &nbsp;&nbsp;Merger and acquisition related expenses (3) | &nbsp;&nbsp;26045  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;—  | &nbsp;&nbsp; 46229  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;—  |
| &nbsp;&nbsp;Other (4) | &nbsp;&nbsp;Other (4) | &nbsp;&nbsp;(3924) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3291  | &nbsp;&nbsp; (4153) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3712  |
| &nbsp;&nbsp;**Adjusted EBITDA** | &nbsp;&nbsp;**Adjusted EBITDA** | &nbsp;&nbsp; $(80201) | &nbsp;&nbsp; $562  | &nbsp;&nbsp; $(172773) | &nbsp;&nbsp; $(106049) |
| &nbsp;&nbsp;(1) | &nbsp;&nbsp;For the years ended December 31, 2022 and 2021, includes $10.3 million and $5.0 million, respectively, in employer payroll taxes. | &nbsp;&nbsp;For the years ended December 31, 2022 and 2021, includes $10.3 million and $5.0 million, respectively, in employer payroll taxes. | &nbsp;&nbsp;For the years ended December 31, 2022 and 2021, includes $10.3 million and $5.0 million, respectively, in employer payroll taxes. | &nbsp;&nbsp;For the years ended December 31, 2022 and 2021, includes $10.3 million and $5.0 million, respectively, in employer payroll taxes. | &nbsp;&nbsp;For the years ended December 31, 2022 and 2021, includes $10.3 million and $5.0 million, respectively, in employer payroll taxes. |
| &nbsp;&nbsp;(2) | &nbsp;&nbsp;Represents losses on equity method investments under the hypothetical liquidation at book value method, net of losses attributable to non-controlling interests. | &nbsp;&nbsp;Represents losses on equity method investments under the hypothetical liquidation at book value method, net of losses attributable to non-controlling interests. | &nbsp;&nbsp;Represents losses on equity method investments under the hypothetical liquidation at book value method, net of losses attributable to non-controlling interests. | &nbsp;&nbsp;Represents losses on equity method investments under the hypothetical liquidation at book value method, net of losses attributable to non-controlling interests. | &nbsp;&nbsp;Represents losses on equity method investments under the hypothetical liquidation at book value method, net of losses attributable to non-controlling interests. |
| &nbsp;&nbsp;(3) | &nbsp;&nbsp;Represents transaction and integration costs directly related to mergers and acquisitions including (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, and (iv) acquired intangible assets expensed to research and development associated with an asset acquisition. | &nbsp;&nbsp;Represents transaction and integration costs directly related to mergers and acquisitions including (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, and (iv) acquired intangible assets expensed to research and development associated with an asset acquisition. | &nbsp;&nbsp;Represents transaction and integration costs directly related to mergers and acquisitions including (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, and (iv) acquired intangible assets expensed to research and development associated with an asset acquisition. | &nbsp;&nbsp;Represents transaction and integration costs directly related to mergers and acquisitions including (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, and (iv) acquired intangible assets expensed to research and development associated with an asset acquisition. | &nbsp;&nbsp;Represents transaction and integration costs directly related to mergers and acquisitions including (i) due diligence, legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses and severance payments, (iii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions, and (iv) acquired intangible assets expensed to research and development associated with an asset acquisition. |
| &nbsp;&nbsp;(4) | &nbsp;&nbsp;For the year ended December 31, 2022, includes $1.2 million in mark-to-market loss on the Access Bio Convertible Notes and Glycosyn Promissory Note and a $5.3 million fair market value remeasurement gain on the convertible promissory notes from Joyn. For the year ended December 31, 2021, includes $3.7 million in mark-to-market adjustments on the Access Bio Convertible Notes and Glycosyn Promissory Note. | &nbsp;&nbsp;For the year ended December 31, 2022, includes $1.2 million in mark-to-market loss on the Access Bio Convertible Notes and Glycosyn Promissory Note and a $5.3 million fair market value remeasurement gain on the convertible promissory notes from Joyn. For the year ended December 31, 2021, includes $3.7 million in mark-to-market adjustments on the Access Bio Convertible Notes and Glycosyn Promissory Note. | &nbsp;&nbsp;For the year ended December 31, 2022, includes $1.2 million in mark-to-market loss on the Access Bio Convertible Notes and Glycosyn Promissory Note and a $5.3 million fair market value remeasurement gain on the convertible promissory notes from Joyn. For the year ended December 31, 2021, includes $3.7 million in mark-to-market adjustments on the Access Bio Convertible Notes and Glycosyn Promissory Note. | &nbsp;&nbsp;For the year ended December 31, 2022, includes $1.2 million in mark-to-market loss on the Access Bio Convertible Notes and Glycosyn Promissory Note and a $5.3 million fair market value remeasurement gain on the convertible promissory notes from Joyn. For the year ended December 31, 2021, includes $3.7 million in mark-to-market adjustments on the Access Bio Convertible Notes and Glycosyn Promissory Note. | &nbsp;&nbsp;For the year ended December 31, 2022, includes $1.2 million in mark-to-market loss on the Access Bio Convertible Notes and Glycosyn Promissory Note and a $5.3 million fair market value remeasurement gain on the convertible promissory notes from Joyn. For the year ended December 31, 2021, includes $3.7 million in mark-to-market adjustments on the Access Bio Convertible Notes and Glycosyn Promissory Note. |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. | &nbsp;&nbsp;Ginkgo Bioworks Holdings, Inc. |
| &nbsp;&nbsp;Segment Information | &nbsp;&nbsp;Segment Information | &nbsp;&nbsp;Segment Information | &nbsp;&nbsp;Segment Information | &nbsp;&nbsp;Segment Information |
| &nbsp;&nbsp;(in thousands, unaudited)  | &nbsp;&nbsp;(in thousands, unaudited)  | &nbsp;&nbsp;(in thousands, unaudited)  | &nbsp;&nbsp;(in thousands, unaudited)  | &nbsp;&nbsp;(in thousands, unaudited)  |
|  | &nbsp;&nbsp;**Three Months Ended December 31,** | &nbsp;&nbsp;**Three Months Ended December 31,** | &nbsp;&nbsp;**Year Ended December 31,** | &nbsp;&nbsp;**Year Ended December 31,** |
|  | &nbsp;&nbsp;**2022** | &nbsp;&nbsp;**2021** | &nbsp;&nbsp;**2022** | &nbsp;&nbsp;**2021** |
| &nbsp;&nbsp;**Revenue:** |  |  |  |  |
| &nbsp;&nbsp;Foundry | &nbsp;&nbsp; $53257  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$34156  | &nbsp;&nbsp; $143666  | &nbsp;&nbsp; $112989  |
| &nbsp;&nbsp;Biosecurity | &nbsp;&nbsp; 45028  | &nbsp;&nbsp; 114338  | &nbsp;&nbsp; 334040  | &nbsp;&nbsp; 200848  |
| &nbsp;&nbsp;Total revenue | &nbsp;&nbsp; 98285  | &nbsp;&nbsp; 148494  | &nbsp;&nbsp; 477706  | &nbsp;&nbsp; 313837  |
| &nbsp;&nbsp;**Segment cost of revenue:** |  |  |  |  |
| &nbsp;&nbsp;Biosecurity | &nbsp;&nbsp; 30218  | &nbsp;&nbsp; 66578  | &nbsp;&nbsp; 204216  | &nbsp;&nbsp; 129690  |
| &nbsp;&nbsp;**Segment research and development expense:** |  |  |  |  |
| &nbsp;&nbsp;Foundry | &nbsp;&nbsp; 99886  | &nbsp;&nbsp; 46015  | &nbsp;&nbsp; 273356  | &nbsp;&nbsp; 160634  |
| &nbsp;&nbsp;Biosecurity | &nbsp;&nbsp;590  | &nbsp;&nbsp; 1165  | &nbsp;&nbsp; 1937  | &nbsp;&nbsp; 31035  |
| &nbsp;&nbsp;Total segment research and development expense | &nbsp;&nbsp; 100476  | &nbsp;&nbsp; 47180  | &nbsp;&nbsp; 275293  | &nbsp;&nbsp; 191669  |
| &nbsp;&nbsp;**Segment general and administrative expense:** |  |  |  |  |
| &nbsp;&nbsp;Foundry | &nbsp;&nbsp; 63723  | &nbsp;&nbsp; 29504  | &nbsp;&nbsp; 168586  | &nbsp;&nbsp; 74407  |
| &nbsp;&nbsp;Biosecurity | &nbsp;&nbsp; 13670  | &nbsp;&nbsp; 9731  | &nbsp;&nbsp; 56353  | &nbsp;&nbsp; 31039  |
| &nbsp;&nbsp;Total segment general and administrative expense | &nbsp;&nbsp; 77393  | &nbsp;&nbsp; 39235  | &nbsp;&nbsp; 224939  | &nbsp;&nbsp; 105446  |
| &nbsp;&nbsp;**Segment operating income (loss):** |  |  |  |  |
| &nbsp;&nbsp;Foundry | &nbsp;&nbsp; (110352) | &nbsp;&nbsp; (41363) | &nbsp;&nbsp; (298276) | &nbsp;&nbsp; (122052) |
| &nbsp;&nbsp;Biosecurity | &nbsp;&nbsp;550  | &nbsp;&nbsp; 36864  | &nbsp;&nbsp; 71534  | &nbsp;&nbsp; 9084  |
| &nbsp;&nbsp;Total segment operating loss | &nbsp;&nbsp; (109802) | &nbsp;&nbsp; (4499) | &nbsp;&nbsp; (226742) | &nbsp;&nbsp; (112968) |
| &nbsp;&nbsp;**Operating expenses not allocated to segments:** |  |  |  |  |
| &nbsp;&nbsp;Stock-based compensation (1) | &nbsp;&nbsp; 111230  | &nbsp;&nbsp; 1672843  | &nbsp;&nbsp;1940920  | &nbsp;&nbsp; 1687607  |
| &nbsp;&nbsp;Depreciation and amortization | &nbsp;&nbsp; 14796  | &nbsp;&nbsp; 7686  | &nbsp;&nbsp; 42552  | &nbsp;&nbsp; 28185  |
| &nbsp;&nbsp;Change in fair value of contingent consideration liability | &nbsp;&nbsp; (1320) | &nbsp;&nbsp; (293) | &nbsp;&nbsp; (1262) | &nbsp;&nbsp; (293) |
| &nbsp;&nbsp;Loss from operations | &nbsp;&nbsp; $(234508) | &nbsp;&nbsp; $(1684735) | &nbsp;&nbsp; $(2208952) | &nbsp;&nbsp; $(1828467) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Includes $10.3 million and $5.0 million in employer payroll taxes for the years ended December 31, 2022 and 2021. Employer payroll taxes for the year ended December 31, 2020 were not material.  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Includes $10.3 million and $5.0 million in employer payroll taxes for the years ended December 31, 2022 and 2021. Employer payroll taxes for the year ended December 31, 2020 were not material.  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Includes $10.3 million and $5.0 million in employer payroll taxes for the years ended December 31, 2022 and 2021. Employer payroll taxes for the year ended December 31, 2020 were not material.  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Includes $10.3 million and $5.0 million in employer payroll taxes for the years ended December 31, 2022 and 2021. Employer payroll taxes for the year ended December 31, 2020 were not material.  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Includes $10.3 million and $5.0 million in employer payroll taxes for the years ended December 31, 2022 and 2021. Employer payroll taxes for the year ended December 31, 2020 were not material.  |

---

------